Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 104 Neoplasms 13 Neoplasm Metastasis 8 Sarcoma 6 Pancreatic Neoplasms 6 Ovarian Neoplasms 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Melanoma 5 Leukemia, Myeloid, Acute 5 Colorectal Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Prostatic Neoplasms 4 Lung Neoplasms 4 Liposarcoma 4 Multiple Myeloma 3 Head and Neck Neoplasms 3 Glioblastoma 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Diseases 3 Brain Neoplasms 3 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm, Residual 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Mantle-Cell 2 Inflammation 2 Estrogen Receptor-positive Breast Cancer 2 Esophageal Squamous Cell Carcinoma 2

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × DILI × palbociclib × Clear all

NCT06367335 2024-04-16

ETIC

University of Milano Bicocca

DILI

Data powered by HemOnc (CC BY 4.0) Colophon ⚡